Interdigital Technology Corporation & Ors. v. Guangdong Oppo Mobile Telecommunications Corp. Ltd. & Ors.

105743230

Samsung Electronics filed applications seeking intervention to prevent the disclosure of its Patent License Agreement (PLA) dated 1st June, 2014, between Samsung and InterDigital Group Companies. The dispute centered on whether the PLA could be shared with defendants' in-house representatives within a confidentiality club established by the court. The Court ultimately directed that the PLA must be shown to the defendants' representatives, subject to specific restrictions.

Jurisdiction
India
Court
Delhi High Court
Case Number
105743230
Decision Date
14 October 2024

Detailed Summary

In the high-stakes world of standard-essential patents (SEPs), the most valuable evidence isn't always the patent itself—it's the secret deals struck around it. When a confidential Patent License Agreement (PLA) becomes the linchpin of a billion-dollar dispute, can a third party successfully keep it hidden from the very parties fighting over its terms? A recent ruling in the InterDigital vs. Oppo battle answered that question with a resounding "no"—and reshaped what founders need to understand about confidentiality in patent litigation.

The dispute unfolded between InterDigital Technology Corporation and Guangdong Oppo Mobile, a clash rooted in the complex world of standard-essential patents and FRAND (Fair, Reasonable, and Non-Discriminatory) licensing. At the heart of the controversy was a Patent License Agreement dated 1st June, 2014, originally signed between Samsung Electronics and the InterDigital Group Companies. Samsung, though not a direct party to the InterDigital vs. Oppo fight, had a powerful interest in keeping the terms of that 2014 agreement under wraps. The court had established a confidentiality club to manage sensitive documents in the case, and the question became: should the PLA be shared with Oppo's in-house representatives inside that club? Samsung intervened aggressively, arguing that disclosure would expose commercially sensitive terms to a direct competitor and undermine the very purpose of confidentiality protections.

Samsung Electronics argued forcefully that the PLA contained commercially sensitive terms that, if disclosed—even within a tightly controlled confidentiality club—would cause irreparable competitive harm. The company insisted that Oppo's in-house representatives, as employees of a direct rival in the mobile technology space, could not be trusted with such sensitive information, regardless of any safeguards. On the other side, the defendants (including Oppo) contended that the PLA was essential to fairly adjudicating the SEP/FRAND dispute at hand. Without access to the actual licensing terms Samsung had agreed to, they argued, they could not meaningfully assess whether InterDigital's offers to them were truly FRAND-compliant. The legal friction was clear: Samsung's right to commercial secrecy versus the defendants' right to a fair hearing on critical evidence.

On 14 October, 2024, the court sided with the need for fair adjudication. The court ultimately directed that the Patent License Agreement must be shown to the defendants' representatives, subject to specific restrictions designed to balance both interests. While the court did not ignore Samsung's concerns about confidentiality, it ruled that the necessity of disclosure for proper adjudication outweighed absolute secrecy. The outcome was plaintiff-favorable, meaning InterDigital's position was strengthened by the disclosure—because the PLA's terms would now serve as a benchmark in evaluating the FRAND nature of InterDigital's licensing offers to Oppo. The court's reasoning reflected a pragmatic principle: in SEP/FRAND disputes, comparable license agreements are often indispensable evidence, and confidentiality clubs exist precisely to enable controlled disclosure rather than to block it entirely.

For founders, IP professionals, and startup leaders operating in technology spaces governed by standard-essential patents, this case delivers a critical lesson: confidential third-party agreements can and will be disclosed by courts when necessary for fair adjudication. If your business model depends on SEP licensing or you are entering into Patent License Agreements, do not assume that confidentiality clauses will shield those deals from judicial scrutiny in related disputes. Build your legal strategy with the assumption that comparable license terms may eventually be exposed to competitors under court-supervised safeguards. More importantly, structure your confidentiality clubs and protective orders proactively—anticipating that "specific restrictions" will be the court's

Practitioner Note

This case demonstrates the evidentiary and procedural standards applied in patent matters before Delhi High Court. Understanding the court's reasoning in Interdigital Technology Corporation & Ors. vs Guangdong Oppo Mobile Telecommunications Corp. Ltd. & Ors. is valuable context for structuring arguments or assessing risk in similar proceedings.

Related Cases

patent1629598

Novartis AgvsHetero Drugs Limited

Novartis AG applied for a patent on the ß-crystal form of imatinib mesylate. Hetero Drugs Limited opposed the application, arguing that the invention was anticipated by prior art and did not meet the enhanced efficacy criteria under Section 3(d) of the Patents Act, 1970. The Tribunal agreed with the opposition, finding that the subject matter was a new form of a known substance without significant improvement in efficacy.

patent167412203

Ms.Y.Aafiya HalimavsHindustan Institute of Technology and Science

The suit was filed by Ms.Y.Aafiya Halima alleging copyright infringement concerning her work on 'Almond and Coconut Cottage Cheese' and seeking relief relating to an Australian patent application for the same product. The dispute was amicably resolved through negotiations, leading to a joint compromise memo.

patent5869677

Astrazeneca AbvsEmcure Pharmaceuticals Limited

The plaintiffs, AstraZeneca, allege that the defendants are infringing their patents related to the compound 'Dapagliflozin', used for treating type-2 diabetes. The plaintiffs seek an injunction against the defendants for not seeking licenses for the patents.

patent124248628

Sun Pharmaeutical Industries LimitedvsIndkus Nexa

Sun Pharmaeutical Industries Limited filed a civil suit against Indkus Nexa and Indo Himalaiyan Herbs Inc. alleging infringement of its registered trademark VOLINI, copyright violation in its packaging art, and passing off due to the use of 'VOLINEX'. The plaintiff sought permanent injunctions and damages. Ultimately, the dispute was resolved through a memorandum of compromise signed by both parties.

patent101118184

Indiamart Intermesh LimitedvsMr Sameer Samim Khan & Ors.

The Delhi High Court ruled in favor of Indiamart Intermesh Limited, granting permanent injunctions against the defendant for infringing its registered trademarks and copyrighted artistic works associated with the 'INDIAMART' brand. The court also ordered the transfer of specific domain names to the plaintiff and awarded punitive damages due to the defendant's alleged nefarious scheme to deceive innocent persons. This judgment strongly affirms the protection afforded to established digital brands operating in the B2B space.

Arctic Invent — IP Strategy

Dealing with a patent challenge?

Whether it's a Section 3(d) rejection, a post-grant opposition, or a FRAND dispute, Arctic's patent litigation team has handled it. Get a strategy call.

Talk to our patent team →

Disclaimer: This page contains an automated summary based on publicly available judicial records. The content is generated for informational purposes only and does not constitute legal advice. Always verify details against the original source judgment before relying on this information for any legal purpose. If you believe any information is inaccurate, please contact us.

Strategy Consult

Facing a similar patent matter?

Arctic's litigation team uses precedent data like this to build winning arguments.

Get a Strategy Call